Browsing for next random stock pick!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OREX ($6.21) Continue to looking good here. <Link Back>
ELTP - Currently under attack my MMs. Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
Revenues Increase by 35%, Product Development Accelerating
Conference Call Scheduled for Tuesday, July 1 at 12:00 PM EDT
NORTHVALE, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral abuse-resistant controlled release product formulations and the manufacturing of generic pharmaceuticals, announced results for the fiscal year ended March 31, 2014 ("Fiscal 2014").
Consolidated revenues were $4.6 million for the fiscal year, an increase of $1.2 million or approximately 35% over consolidated revenues for the prior year. During the fiscal year, Elite launched 3 new products, acquired 12 approved ANDA's, and saw strong and sustained growth in its line of commercial generic products. This marks the second consecutive year in which Elite achieved revenue growth in excess of $1 million.
During Fiscal 2014, Elite continued to expand and accelerate the development of its abuse resistant opioid technology, successfully completing a bio equivalence study, initiating a second bioequivalence study and a human abuse liability study and securing additional patents in the U.S. and internationally. As a result, product development costs increased from less than $1 million in the prior year to almost $4 million in Fiscal 2014. Elite expects to file the first of its range of abuse resistant opioid products by the end of calendar 2014.
Elite's balance sheet was also its strongest on record, reporting a working capital surplus of $3.8 million, the first working capital surplus in 5 years. Based on the strength of its balance sheet, combined with the growth in commercial operations and access to significant financing, management determined that Elite is sufficiently capitalized to operate as a going concern. Elite's independent auditors agreed with this determination, and have issued an unqualified opinion without a going concern paragraph. This is the first audit opinion without a going concern paragraph since 2002.
Nasrat Hakim, CEO of Elite commented, "Fiscal 2014 will be known as the year of Elite's turnaround. We successfully completed a bioequivalence study for ELI-200, initiated other human trials, and are well positioned to file the first of our abuse resistant opioid products by the end of this year. We have emerged as one of the leaders in the development of abuse deterrent opioids. In addition, we launched three new generic products and acquired twelve additional generic products, which we expect to provide a stable and growing foundation of revenues to sustain us on an ongoing basis. I want to thank and congratulate the entire Elite team for the spectacular accomplishments during Fiscal 2014, on which we continue to build and move forward."
The Company will host a conference call to discuss the results of operations and provide an update on recent business developments on Tuesday, July 1, 2014 at 12 Noon EDT. Company executives will conduct a question and answer session following their remarks.
To access the conference call:
Domestic callers: (800) 346-7359
International callers: (973) 528-0008
Conference Entry Code: 98840
A digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until July 15, 2014 by dialing:
Domestic callers: (800) 332-6854
International callers: (973) 528-0005
Conference entry code: 98840
The financial statements can be viewed in Elite's Annual Report on Form 10-K at: http://www.elitepharma.com/sec_filings.asp.
Ref. http://finance.yahoo.com/news/elite-pharmaceuticals-inc-reports-financial-180537076.html
VHI ($6.45) Again, very nice bouncing back EOD here <link back>
RTK ($2.57) Indeed it's ending nicely here <link back>
BOARD: I will try o update any stocks I take position as day/trade as much as I can with IBOX. Things move so fast with daytrade it's hard to update.
VHI ($6.38) Very nice.
Ahhhhh now I see :)
ETRM - I have a little doubt with this one..was great in the past..what's going on with it now?
ARQL ($1.53) Hanging strong regardless of Russell. Should be expecting update soon regarding phase 2 (I think)
VHI - Back online here. Good times was at $6.09 ---> now $6.30
MNGA - Trying to reach out $1.55. If not today then tomorrow.
RTK ($2.53) Pretty nice <link back>
Man you guys are rocking it today! I am feeling left out here lol.
PRAN ($2.34) Get in early and wait for the "WATCH for possible breakout above $2.68". Target for me is $3.90 here.
Thanks basssque! Ref. is on the ibox.
VHI * Correction not VHO
VHO ($6.19) Getting closer to $6 here.
MNGA ($1.51) Soon will take off so far so good.
RTK ($2.47) Inching it up here <link back>
FOLD ($3.90) Amicus Therapeutics Provides Updates and Final Analysis Plan for Phase 3 Fabry Monotherapy Study 012
ref. http://finance.yahoo.com/news/amicus-therapeutics-provides-updates-final-110000426.html
CPRX - Will re-connect probably mid-day. Keep watch.
GERN - Nice!
VHI - ($6.44) Watching for this to hug closer to $6. $6.40 might be a good start and add more on dip. No doubt people assume it could be sold (going private) after Mr. Simmons's unfortunate passing. It is a high risk to speculate with this..but keep in mind this stock was $14 sometime in Feb, I believe. $9 something back in March 2014.
GERN ($3.16) - WATCH for possible breakout above $3.28 (becareful breakdown is below $2.96)
DRWI ($2.06) Watch it. It still got room to grow <link back>
KBIO ($2.37) Very nice. Mid-day watch.
ISR - Very nice!
LIQD ($1.89) Here we go <link back>
RTK ($2.44) Watch it today <link back>
VHI ($6.73) Watch it <link back>
RGEN ($22.92) Break out coming <link back>
You are absolutely right! Forgot about all that Russell business.
BREAK: RTK - WATCH for possible breakout above $2.49 <link back>
ARIA - On watch here also.
ARQL - Look at that Vol. Folks placing bet for BIO land's with FDAs June 30 here.
BOARD: I am seeing some goodies here for Monday. $KBIO, $TRGT, $RTK...I also have $VHI (weird and wacky with potential of going private and share at $9)
TRGT - This one's for June 30?
KBIO - Did take out $2.28 (big time) my first target would be $2.56 is within reach but it's going to surpass this with this kinda Vol. Monday's radar here. <link back>
KBIO - 408K AH? WHOA Massive!
RTK - This one on Monday's radar here. I will be jumping on-board. Previous break out alerted was good. Let's see how this break will do. Aiming $2.68 - $2.70s.